Corcept Therapeutics

CORT

Market cap $8.26B

Overview Fund Activity

78.40 USD

+3.22

4.28%

At close Updated Sep 18, 12:15 PM EDT

1 day

4.28%

5 days

5.55%

1 month

9.25%

3 months

10.05%

6 months

38.76%

Year to date

56.89%

1 year

85.47%

5 years

335.8%

10 years

1,443.31%

About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Employees: 500

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

11% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 63

0% more funds holding

Funds holding: 416 [Q1] → 416 (+0) [Q2]

2% less repeat investments, than reductions

Existing positions increased: 152 | Existing positions reduced: 155

3.53% less ownership

Funds ownership: 78.04% [Q1] → 74.51% (-3.53%) [Q2]

36% less capital invested

Capital invested by funds: $9.14B [Q1] → $5.87B (-$3.27B) [Q2]

39% less call options, than puts

Call options by funds: $51.5M | Put options by funds: $84.9M

63% less funds holding in top 10

Funds holding in top 10: 16 [Q1] → 6 (-10) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$121

54% upside

Avg. target

$131

66% upside

High target

$140

79% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity Edward Nash	$140	Buy Maintained	10 Sep 2025
Piper Sandler David Amsellem	$121	Overweight Maintained	1 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CORT published over the past 30 days

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

These companies are expected to continue growing revenue at a rapid pace through 2027.

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

Zacks Investment Research

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept's New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Zacks Investment Research

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

Zacks Investment Research

Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?

CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.

Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early

Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment issues, but true demand and revenue growth may be accelerating as a large new market is penetrated, pharmacy capacity expands, and new products launch. Physician adoption of Corcept's therapies is ramping earlier than we expected, supporting a long-term outlook for 30-50% annual revenue growth and significant market expansion.

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secretary Joseph K. Belanoff - Co-Founder, President, CEO & Director Roberto W.

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

Zacks Investment Research

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

Zacks Investment Research

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.32 per share a year ago.

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results “The second quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a re.

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™